NASDAQ: ACHV
Achieve Life Sciences Inc Stock Forecast, Predictions & Price Target

Analyst price target for ACHV

Based on 3 analysts offering 12 month price targets for Achieve Life Sciences Inc

Min Forecast
$12.00+163.16%
Avg Forecast
$14.67+221.64%
Max Forecast
$19.00+316.67%

Should I buy or sell ACHV stock?

Based on 3 analysts offering ratings for Achieve Life Sciences Inc.

Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ACHV's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ACHV as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their ACHV stock forecasts and price targets.

ACHV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-04-21
lockedlocked$00.00+00.00%2026-04-16
lockedlocked$00.00+00.00%2025-11-25

1 of 1

Forecast return on equity

Is ACHV forecast to generate an efficient return?

Company
420.19%
Industry
73.9%
Market
159.33%
ACHV's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ACHV forecast to generate an efficient return on assets?

Company
216.36%
Industry
30.65%
ACHV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ACHV earnings per share forecast

What is ACHV's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$1.30
Avg 2 year Forecast
-$0.96
Avg 3 year Forecast
$0.33

ACHV revenue forecast

What is ACHV's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$41.6M
Avg 3 year Forecast
$147.3M

ACHV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ACHV$4.56$14.67+221.64%Strong Buy
ARCT$8.41$17.00+102.14%Buy
REPL$2.87$5.00+74.22%Buy
CDXS$2.75N/AN/A
OBIO$4.01$15.67+290.70%Strong Buy

Achieve Life Sciences Stock Forecast FAQ

Is Achieve Life Sciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: ACHV) stock is to Strong Buy ACHV stock.

Out of 3 analysts, 1 (33.33%) are recommending ACHV as a Strong Buy, 2 (66.67%) are recommending ACHV as a Buy, 0 (0%) are recommending ACHV as a Hold, 0 (0%) are recommending ACHV as a Sell, and 0 (0%) are recommending ACHV as a Strong Sell.

If you're new to stock investing, here's how to buy Achieve Life Sciences stock.

What is ACHV's earnings growth forecast for 2026-2028?

(NASDAQ: ACHV) Achieve Life Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.69%.

Achieve Life Sciences's earnings in 2026 is -$54,648,000.On average, 10 Wall Street analysts forecast ACHV's earnings for 2026 to be -$69,419,620, with the lowest ACHV earnings forecast at -$94,437,091, and the highest ACHV earnings forecast at -$45,839,630. On average, 10 Wall Street analysts forecast ACHV's earnings for 2027 to be -$50,881,457, with the lowest ACHV earnings forecast at -$86,089,061, and the highest ACHV earnings forecast at -$12,298,437.

In 2028, ACHV is forecast to generate $17,787,480 in earnings, with the lowest earnings forecast at -$15,130,805 and the highest earnings forecast at $76,585,723.

What is ACHV's revenue growth forecast for 2026-2028?

(NASDAQ: ACHV) Achieve Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.02%.

Achieve Life Sciences's revenue in 2026 is $0.On average, 9 Wall Street analysts forecast ACHV's revenue for 2026 to be $0, with the lowest ACHV revenue forecast at $0, and the highest ACHV revenue forecast at $0. On average, 10 Wall Street analysts forecast ACHV's revenue for 2027 to be $2,215,475,621, with the lowest ACHV revenue forecast at $1,043,503,765, and the highest ACHV revenue forecast at $6,662,452,098.

In 2028, ACHV is forecast to generate $7,842,782,632 in revenue, with the lowest revenue forecast at $2,093,609,288 and the highest revenue forecast at $17,243,899,713.

What is ACHV's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ACHV) forecast ROA is 216.36%, which is higher than the forecast US Biotechnology industry average of 30.65%.

What is ACHV's Price Target?

According to 3 Wall Street analysts that have issued a 1 year ACHV price target, the average ACHV price target is $14.67, with the highest ACHV stock price forecast at $19.00 and the lowest ACHV stock price forecast at $12.00.

On average, Wall Street analysts predict that Achieve Life Sciences's share price could reach $14.67 by Apr 21, 2027. The average Achieve Life Sciences stock price prediction forecasts a potential upside of 221.64% from the current ACHV share price of $4.56.

What is ACHV's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ACHV) Achieve Life Sciences's current Earnings Per Share (EPS) is -$1.25. On average, analysts forecast that ACHV's EPS will be -$1.30 for 2026, with the lowest EPS forecast at -$1.77, and the highest EPS forecast at -$0.86. On average, analysts forecast that ACHV's EPS will be -$0.96 for 2027, with the lowest EPS forecast at -$1.62, and the highest EPS forecast at -$0.23. In 2028, ACHV's EPS is forecast to hit $0.33 (min: -$0.28, max: $1.44).

What is ACHV's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ACHV) forecast ROE is 420.19%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.